Enterprise Value

189M

Cash

25.71M

Avg Qtr Burn

-7.966M

Short % of Float

7.71%

Insider Ownership

33.27%

Institutional Own.

13.71%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
CAN-2409 Details
Cancer, Solid tumor/s, Intermediate/high-risk Prostate cancer

Phase 3

Data readout

Phase 2

Data readout

CAN-2409 Details
Cancer, Solid tumor/s, Low-to-intermediate-risk non-metastatic prostate cancer

Phase 2

Data readout

CAN-2409 + Valacyclovir w/ PD-(L)1 targeting agents Details
Lung cancer, Cancer, Solid tumor/s, Non-small cell lung carcinoma

Phase 2

Update

CAN-3110 Details
Solid tumor/s, Cancer, Glioma

Phase 1b

Data readout

CAN-2409 + Opdivo Details
Cancer, Glioma, Solid tumor/s

Failed

Discontinued